

Special Issue

State-of-the-Art Gene-Target and Cell Therapy in Poland

Message from the Guest Editors

This Special Issue aims to publish contributions on all aspects of the study of molecular and epigenetic biology as well as gene and cell therapy in Poland. Research articles and reviews are sought which provide insight into any aspects of gene and cell therapies in Poland. Topics include but are not limited to:

- Personalized diagnostic and therapy;
- Target vectors for gene therapies;
- Molecular processes of cell division, senescence, and cell death;
- Stem-cell-based therapies;
- Cell-vehicle-targeting strategies;
- Gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics;
- Antisense oligonucleotide technology;
- Molecular mechanisms and models of disease;
- Suicide gene therapy;
- Clinical genome editing;
- Pre-clinical animal/in vitro studies to assess safety of gene and cell therapy products;
- Epigenetic aims of therapy;
- Signaling networks and system biology;
- Molecular anti-cytokine therapies in diseases with cell hyperproliferation;
- Gene and immune therapies in children and adults with a wide range of disorders;
- Gene and cellular therapies.

Guest Editors

Dr. Anita Lyssek-Borón

Department of Ophthalmology, Faculty of Medicine in Zabrze, Academy of Silesia in Katowice, Katowice, Poland

Dr. Beniamin Grabarek

Collegium Medicum, WSB University, 41-300 Dabrowa Gornicza, Poland

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/139657

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).